At Cancer Care Associates, we believe in the power of cancer research and the hope it gives to millions of patients worldwide. In fact, we have more patients involved with national and pharmaceutical clinical trials than any other cancer treatment center in the central valley. Our participation in this research has improved cancer care for people in our geographic region and around the world. These clinical trials cover a broad spectrum of diagnosis and include cancer, non-cancer, prevention and symptom management studies.
Cancer Care Associates is dedicated to cancer research with ongoing clinical trials with specific departments focused solely on these studies. By participating in these clinical trials, Cancer Care Associates has privileged access to treatment options that would not otherwise be available. Implementing the proper techniques with world-renowned research institutions is another example of Cancer Care Associates committment to treatment. These leading edge therapies significantly increase treatment options for our patients, which aide in the plight against cancer. These trials not only have a direct benefit on our patients’ health, but they deliver positive results which can be shared and utilized in clinics worldwide. We take pride in our ongoing clinical trials with various research groups such as the prestigious Mayo Clinic. It is our quest to continually strive to reduce the number of cancer patients, deliver the most advanced forms of procedures and promote novel approaches to ongoing treatment.
Cancer Care Associates are members of the following research groups:
• NCCTG (North Central Cancer Treatment Group affiliate through
The Mayo Clinic)
http://ncctg.mayo.edu/
Cancer Care Associates are currently involved in clinical trials concerning breast cancer, colorectal cancer, head and neck cancers, lung cancer and ovarian cancer, as well as studies focusing on pain control and sleep improvement.
Cancer Care Associates Trials Open to Accrual
Bone Marrow
CBIO-BB005.V.1 Biospecimen Collection and Use for Future
Scientific Research of Bone Marrow Biopsies from ALL, AML, CLL, MM and
CML patients.
Breast
D-CARE: A randomized, double-blind, placebo-controlled
study of Denosumab for women with early-stage breast cancer at high
risk of recurrence with lymph node involvement or tumor size > 5
cm or locally advance disease. Patients must be scheduled to receive
standard of care adjuvant or neo-adjuvant chemotherapy and/or endocrine
therapy and/or HER-2 targeted therapy.
(ER/PR + or -) (Her2 + or -)
Geron CP14B014: A randomized study of Imetelstat in
combination with Paclitaxel (with or w/out Bevacizumab) in Adenocarcinoma
patients with locally recurrent or metastatic breast cancer.
J&J 212082BCA2001 Phase 2 randomized, open-label
study of Abiraterone Acetate plus prednisone with or without Exemestane
in postmenopausal women with metastatic breast cancer progressing after
Letrozole or Anastrozole Therapy.
Breast and Gynecological
Merrimack MM-121-04-01-04: Phase 1 Pharmacologic &
Pharmacodynamic study of MM-121 in combination with Paclitaxel in patients
with advanced gynecologic and breast cancers.
Colorectal
I4T-MC-JVBB: A randomized, double-blind, study of Irinotecan,
Folinic Acid, and 5-Fluorouracil (Folfiri) plus Ramucirumab or Placebo
in patients with metastatic colorectal carcinoma progressive during
or following first-line combination therapy with Bevacizumab, Oxaliplatin,
and a Fluoropyrimidine.
Lung Cancer.
MORAb-003-009: A Randomized, Double-Blind, Placebo-Controlled,
Study of the Safety and Efficacy of Farletuzumab in Combination with
a Platinum Containing Doublet in Chemotherapy-Na?ve Subjects with Stage
IV Adenocarcinoma of the Lung
I4T-MC-JVBA: A randomized, double-blind, study of Docetaxel
and Ramucirumab versus Docetaxel and Placebo in the treatment of advanced
stage NSCLC following disease progression after one prior platinum-based
therapy.
Pain
NP2/P2/10/2: A Phase II, Randomized, Double Blind,
Placebo-controlled, Multicenter Study to Investigate the Impact of NP2
in Subjects with Intractable Pain due to Malignancy
